Nicholas T. Hertz, PhD
Co-Founder and Chief Science Officer at Mitokinin LLC
Location: San Francisco, California, United States
Nicholas T. Hertz, PhD, is the Co-Founder and CSO of Mitokinin Inc. The companyís goal is to develop neo-substrates for PINK1. During his graduate research, he discovered that PINK1 could utilize the N6 modified ATP analog kinetin triphosphate (KTP) more efficiently than ATP. Historically, chemists and biologists have had to limit their investigations to inhibitors of overactive kinases (such as oncogenic kinases) or drugs that bound to allosteric regulatory sites. The development of neo≠-substrates to treat underactive kinases could represent a new weapon in the fight against diseases that are associated with kinase underactivity and potentially presages a new class of activity-enhancing neo-substrate therapeutics. Dr. Herz graduated magna cum laude from the University of California, Los Angeles with a bachelorís degree in biochemistry. He earned a doctorate in chemical biology at the University of California, San Francisco, where he studied chemical genetic techniques to elucidate kinase signaling pathways with Drs. Kevan Shokat and Al Burlingame.